Biogen to present Empaveli long-term data at ASN Kidney Week
Tweet Send to a Friend
Biogen Inc. (Nasdaq: BIIB) will present new data from its nephrology portfolio, including 76-week results for its approved therapy Empaveli ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




